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Purpose or Objective: The Calypso 4D Localization System 
consists in an electromagnetic detection of implanted Beacon 
transponders in order to continuously track their moves. The 
use of this system requires a specific couch top and the 
introduction in the treatment beam of an electromagnetic 
array. The purpose of this study is to quantify the dosimetric 
impact of the new material introduction in photon beams. 
 
Material and Methods: At first, the QFix kVue Calypso couch 
top and the array attenuation was evaluated by comparing 
the dose measurements with Eclipse TPS dose prediction for 
2 energies (6MV FF and 6MV FFF) and 2 rail configurations 
(rails in and rails out). Dose measurements at the isocenter 
were performed with a cylindrical water-equivalent 
phantom, a 0.125cc ionization chamber, a 10*10cm² field size 
at 39 gantry angles. The beams between 315 and 45° allowed 
analyzing the electromagnetic array attenuation. The beams 
between 90 and 270° were used for couch attenuation. 
Secondly, the dosimetric impact was analyzed on 20 RapidArc 
treatment plans of prostate (10 with 6MV FF and 10 with 6MV 
FFF). Dose distributions were recalculated in the cylindrical 
phantom and the dose prediction at the isocenter was 
compared to the dose measurement with the 0.125cc 
ionization chamber using 2 configurations: classical 
treatment (with kVue IGRT couch top and rails out) and 
treatment with Calypso (QFix kVue Calypso couch top, rails 
out and the electromagnetic array). 
 
Results: 
 
 
 
In the configuration of rails out, the mean attenuation of the 
couch was 2.91% for X6 and 3.45% for X6FFF with a maximum 
of 12.02% and 13.19% for X6 and X6FFF, respectively. In the 
configuration of rails in, the mean attenuation was 3.25% for 
X6 and 3.90% for X6FFF with a maximum of 9.79% and 11.14% 
for X6 and X6FFF, respectively. Besides, the mean 
attenuation of the array was 1.15% and 1.67% for X6 and 
X6FFF, respectively. As regards the impact of global Calypso 
system on RapidArc treatment plans, the mean deviation with 
a classical treatment was -0.61% [-0.8%; -0.3%] for X6, and -
0.31% [-0.86; 0.43] for X6FFF. 
 
Conclusion: For the fixed beams, the attenuation is not 
negligible when a beam crosses directly a support rail in 
particular. The errors in dose calculation can be more of 10%. 
However, for RapidArc treatments with X6 and X6FFF, the 
dosimetric impact of the QFix kVue Calypso and the array is 
not significant. 
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Purpose or Objective: Skin electron irradiation is a 
treatment modality for mycosis fungoides. An overlapping 
and/or abutting field technique with the patient lying on a 
stretcher is used with at least two oblique 40x40 cm²; 4 MeV- 
overlapping fields at 25/335 gantry angles at SSD=170 cm 
both about 12 cm lateral of patient mid-line. If two fields fail 
to cover the entire affected skin additional abutting oblique 
fields are added in cranio-caudal direction. Using 3 pairs of 
fields, the entire anterior (or posterior) body is covered. 
During commissioning of a new Elekta Synergy accelerator 
special attention was given in the search of an optimal angle 
incidence and field matching. 
 
Material and Methods: A linear array (PTW LA-48) positioned 
in a polystyrene phantom is used to evaluate longitudinal and 
lateral dose profiles at 1 and 4 mm depth. Two different 
angles of incidence (± 25° and ± 30°) and three different 
abutment gaps (0-32-64 mm; common multipliers of the 8 
mm interdetector distance of the LA-48) are evaluated. 
Prescription dose point is corresponding to the dose value at 
4 mm depth of the central axis dose of the most cranial beam 
pair. Treatment length is defined as the distance between 
the most cranial and most caudal 90% dose point. Beam 
spread is calculated over the entire treatment length, beam 
flatness (1) over 0.9 times the treatment length. 
(1) Podgorsak p.196 
 
Results: Both gantry angle pairs show a remarkable flat 
summed dose profile over the entire range of the LA-48 (3.0-
3.2% for ± 25°; 2.3.-2.4% for ± 30°). As expected maximal 
dose levels are decreasing with increasing obliqueness 
resulting in more depth-related dose homogeneity. Cranio-
caudal measurements show a radiation field increase of 1.5-2 
cm (50% field dose boundary) compared to the light field . 
The initial 6 field light field abutment method results in dose 
spreads of 3.5% and 5.6% (4-1 mm depth) and dose flatness of 
4.7% and 6.1%. Introducing 32 mm gaps improves dose data to 
2.5% and 2.8% in spread and to 3.3% and 3.8% in flatness. 64 
mm gaps result in a spread of 4.3% and 3.6% and a flatness of 
7.5% and 6.0% (fig. 1). The corresponding treatment length 
increases from 168 cm (no gaps) to 178 cm (32 mm gaps) and 
to 187 mm (64 mm gaps). 
 
 
 
Conclusion: The general conclusion is that for mycosis 
fungoides treatments, using oblique fields with dedicated 
abutment in cranio-caudal direction the general accepted 
overall dose homogeneity of ±10% is more than met on a flat 
surface equivalent to the size of a human body using 6 
oblique fields.  
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Purpose or Objective: To study dose distributions in chest 
wall with thickness around or less than 15 mm and to 
evaluate the accuracy of Eclipse and Oncentra treatment 
planning algorithms in phantom and patient geometries. 
 
Material and Methods: Measurements by thermo luminescent 
dosimeters and gafchromic film are performed on a 
cylindrical phantom with air cavity representing the lung. 
Tangential 6 MV open beam is applied on the phantom and 
dose profiles from the surface toward the geometrical center 
S712                                                                                                                                                  ESTRO 35 2016 
_____________________________________________________________________________________________________ 
of the phantom are obtained at beam axis entrance and exit, 
as well as laterally. Dose distributions for two patients are 
calculated for clinical plans involving 6 MV and 15 MV photon 
beams and field-in-field techniques. Three volumes are 
studied, namely, PTV (516 cm3) and CTVT (10 cm3) for 
patient one, and PTVT (117 cm3) for patient two. 
Calculations in the case of phantom and patient geometries 
are performed by Eclipse AAA and Acuros XB algorithms and 
by Oncentra CC algorithm. Corresponding Monte Carlo dose 
calculations are carried out using EGSnrc/BEAMnrc software. 
Estimates like D98% (dose to 98% of the volume) and V95% 
(the volume receiving 95% of the dose) are used when 
comparing the dose distributions. The accuracy of the 
different algorithms when including a bolus is investigated. 
 
Results: Measurements in the phantom case show a negligible 
dose decrease at the phantom-in-air interface but more than 
10% dose decrease at this interface laterally or at beam exit. 
Large uncertainties in calculated data are detected in the 
interface regions, namely up to 4 mm depth from the 
phantom-air interface and 2 mm depth from the phantom-in-
air interface. In the patient cases, deviations less than 3% are 
observed for PTV and CTVT for the dosimetry parameters 
D98% D2% and V105% obtained by the different algorithms 
and the Monte Carlo method. For PTVT, the largest 
deviations are between AAA and Monte Carlo data, for 
example, 3.6% for D98% and 9.2 % for V105%. The results are 
explained by the fact that PTV is large and eventual 
uncertainties at the boundary has smaller effect on the dose 
volume histograms. CTVT is small, however, the distance 
from the CTVT contour to the surface and to the lung 
interface is 4 mm or more at each slice. In the third case, a 
large partial volume of PTVT is located near the lung 
interface where the dose uncertainties are large. 
Furthermore, it has been found, that the algorithms reflect 
properly the dose changes due to bolus except for AAA, 
where the dose volume histograms for CTVT obtained with 
and without bolus can’t be distinguished. 
 
Conclusion: Partial volume located near the lung interface 
has major effect on target coverage. The measured dose 
decrease and the uncertainties of the treatment planning 
algorithms near interfaces should be taken into account when 
establishing guidelines for target delineation and coverage 
for patients with thin chest wall. 
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Purpose or Objective: The Hi-Art Helical TomoTherapy unit 
is a linear accelerator equipped with an on-board CT detector 
array. It delivers radiation in a helical fashion with daily CT 
imaging for image guidance and beam monitoring. In vivo 
dosimetry is a recommended part of treatment with the 
potential of improving patient safety. Conventional 
approaches of in vivo dosimetry cannot be implemented for 
TomoTherapy due to the rotational nature of the system and 
thus transit dosimetry is required. This study has investigated 
the use of the detector sinogram in performing transit 
dosimetry by modelling how the primary photons are 
influenced by scatter geometry for a static and helical field. 
The aim has been to produce a semi-empirical model of the 
exit detector signal and investigate factors that influence the 
signal at the imaging panel of a TomoTherapy unit.  
 
Material and Methods: The detector signal profile (detector 
sinogram) is extracted for the DICOM data for each 
procedure. It contains the response at each detector channel 
and for each projection. The exit detector response for an 
open field is measured in-air with a moving couch for a static 
and helical delivery. The exit detector sinogram for an in-air 
measurement has been used as an input into a signal 
reconstruction model of the exit detector sinogram when a 
scattering medium is positioned on the couch. A simple ray-
tracing model has been produced using narrow beam 
conditions for the attenuation of the beam in a cylindrical, 
uniform phantom (Tomo® Cheese Phantom). The model relies 
on TPR data previously determined in the department as 
shown in Thomas et al., (2012).  
 
Results: The simulated sinogram agrees with the measured 
sinogram for both the static and helical deliveries within ± 
10% in the central region of the phantom. At the edge of the 
phantom this increases to ±15% due to set-up issues. 
 
 
Figure 1 shows a single projection (7 degrees) taken from the 
sinogram data for the measured and modeled exit detector 
sinograms. 
 
Conclusion: At this stage of development, the model shows 
promise in use as an independent check tool. However, 
second order corrections, such as scatter, should be 
incorporated if the model is to be clinically used. Further 
work is also required to reduce set-up errors, i.e. by imaging 
the phantom prior to measurement. 
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Purpose or Objective: Compass© (IBA, Schwarzenbruck, 
Germany) is a 3D pre-treatment plan verification system. The 
linac fluence is measured with an ion chamber array (MatriXX 
(IBA)). Then via a detector fluence model and collapsed cone 
algorithm [1], the dose is calculated on the patient’s 
planning CT. It has been demonstrated that Compass can 
validate VMAT plans (73-99% gamma passing rate at 3%/3mm 
[2]) although it does introduce some dose blurring [3]. 
However, occasional failures do occur in plan verification 
using Compass (i.e. a significant variation on a DVH 
parameter or reduced gamma pass rate). The purpose of this 
work was to understand whether failures were due to genuine 
errors (such as treatment delivery or calculation) or due to 
the limitations and uncertainties of the Compass 
methodology. To achieve this, EBT3 film was used as best 
estimate of the true delivered dose distribution for prostate 
VMAT plans. 
 
Material and Methods: Six fields which were characteristic of 
segments from previously failed plans were measured with 
EBT3 film using advanced triple-channel dosimetry 
techniques (via FilmQAPro). These were then compared 
against Compass and the TPS (Pinnacle 9.8) doses using 
profile and 2D global gamma analysis. Twelve film 
